Evidence map›Paper›PMID 26577189›Full record

ArticleRadiation oncology (London, England)2015

A comparative dosimetric study of left sided breast cancer after breast-conserving surgery treated with VMAT and IMRT.

Hongfu Zhao, Mingyuan He, Guanghui Cheng, Dongmei Han, Ning Wu, Dan Shi, Zhipeng Zhao, Jianxue Jin

Abstract readComparative Study
In one paragraph

Article in Radiation oncology (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Examination of the dose distribution of volumetric modulated arc radiotherapy using a high-definition multi-leaf collimator for breast cancer patients with irradiated regional lymph nodes.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hongfu ZhaoDepartment of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Mingyuan HeDepartment of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Guanghui ChengDepartment of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China. chengghcjuh@sina.com.
Dongmei HanDepartment of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Ning WuDepartment of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Dan ShiDepartment of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Zhipeng ZhaoDepartment of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Jianxue JinDepartment of Radiation Physics, Elekta China Co. Ltd, Beijing, 100101, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposesThis study compared VMAT and IMRT plans for intact breast radiotherapy for left sided breast cancer and evaluated the irradiated dose of planning target volume and OARs, especially focusing on heart and coronary artery. MATERIALS AND

methodsEleven patients with left sided breast cancer whose breast was relatively smaller (the mean volumes is 296 cc) treated with breast-conserving surgery were prescribed radiotherapy of 50 Gy in 25 fractions using two or four-field step and shoot IMRT (2 or 4-F IMRT), and one or two-arc VMAT (1 or 2-arc VMAT). The 10 Gy electron boost to the tumor bed after delivery of 50 Gy was not included in the analysis. Multiple planning parameters for the PTV and the PRV-OARs were measured and analyzed.

resultsTreatment plans generated using VMAT had better PTV homogeneity than the IMRT plans. For the PRV-OARs, the 1-arc VMAT had significantly higher Dmean and V5 for left lung and heart, and showed worse Dmean for liver, esophagus, spinal cord, contralateral lung and breast. In contrast, the 2-arc VMAT and the 2-F or 4-F IMRT plans showed better results for the PRV-OARs than the 1-arc VMAT. However, for the heart and coronary artery, the 1-arc VMAT showed better V20 and V40 compared with the other plans. Moreover, the 2 F-IMRT had specially advantage on V5 and V20 for heart and V5 for coronary arteries, the 2-F IMRT also showed a greater MU and treatment times. Using the table of quality score to evaluate the plans, we found that 2-F IMRT had the highest scores of 13, followed by the 2-arc VMAT plan (10 points) and 1-arc VMAT plan (8 points), and finally the 4-F IMRT plan (6 points). Moreover, when a dose comparison for heart minus coronary artery was calculated, the V20 and V40 for the rest of heart in all plans were very small and closed, indicating the dose to the coronary artery contributed dramatically to the high dose volumes for the entire heart.

conclusionsCompared to other plans, the 2-F IMRT plan with fewer monitor units and shorter delivery time is an appropriate technique for left sided breast cancer, which achieved good PTV coverage and sparing of organs at risk besides for the heart and coronary artery.

Indexed as

AdultAgedAged, 80 and overFemaleHumansMastectomy, SegmentalMiddle AgedOrgans at RiskRadiometryRadiotherapy DosageRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedUnilateral Breast Neoplasms

Identifiers

PMID26577189
PMCPMC4650319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.